
Maureen Kenny
Executive Editor at Pharma Intelligence
Executive editor at Informa Pharma Intelligence (Pink Sheet). All opinions are my own.
Articles
-
Oct 19, 2024 |
insights.citeline.com | Maureen Kenny
Gilead's Biktarvy Set For EU Approval 30 Apr 2018 • By Maureen KennyA combination therapy – Gilead Science’s Biktarvy – a hybrid medicine and a generic can look forward to EU approval after getting the OK from the EMA’s drug evaluation committee last week. Gilead's new HIV combination has been recommended for EU approval
-
Apr 21, 2023 |
higheredtoday.org | Maureen Kenny
-
Apr 6, 2022 |
pink.pharmaintelligence.informa.com | Maureen Kenny
-
Mar 1, 2022 |
pink.pharmaintelligence.informa.com | Maureen Kenny
-
Feb 27, 2022 |
pink.pharmaintelligence.informa.com | Maureen Kenny
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 1K
- Tweets
- 2K
- DMs Open
- No

Novartis Restructure: With top names departing, refocused therapeutic priorities & new targets set, this @PharmaScrip article by @awmcconaghie is important reading for all in the industry, from biotech partners (and would-be partners) to big pharma peers. https://t.co/ZwokWkevMQ

Alexander Natz of @EUCOPE explains in this @PharmaPinkSheet article the new EU regulation on health technology assessment, one of the biggest developments to affect the pharma industry in over a decade. https://t.co/h31VR0HU1u

RT @DIA_Europe: Welcome to #DIAEurope2022 ! #Day1 we are so excited to be face-to-face in Brussels! Our three-day event is just beginning…